BCMA/TNFRSF17 Protein, Human, Recombinant (His)

Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.

规格	价格/CNY		数量
50 μg	￥ 2,160	现货
100 μg	￥ 3,830	5日内发货
200 μg	￥ 6,770	5日内发货
500 μg	￥ 14,320	5日内发货

规格

价格/CNY

货期

数量

50 μg

￥ 2,160

现货

100 μg

￥ 3,830

5日内发货

200 μg

￥ 6,770

5日内发货

500 μg

￥ 14,320

5日内发货

生物活性

1. Immobilized Human BAFF at 2μg/mL (100 μl/well) can bind Human BCMA , The EC50 of Human BCMA is 30-80 ng/mL. 2. Immobilized Mouse TNFSF13 at 2μg/mL (100 μl/well) can bind Human BCMA , The EC50 of Human BCMA is 0.6-2.1 ng/mL.

TargetMol Bioactive

产品描述

种属	Human
表达系统	HEK293
标签	His
蛋白编号	Q02223-1
别名	BCMA, TNFRSF13A, CD269, tumor necrosis factor receptor superfamily member 17, BCM
蛋白构建	A DNA sequence encoding the human TNFRSF17 (NP_001183.2) (Met1-Ala54) was expressed with a polyhistidine tag at the C-terminus.
蛋白纯度	≥ 95 % as determined by SDS-PAGE. ≥ 95 % as determined by SEC-HPLC.
分子量	7.3 kDa (predicted)

内毒素	< 1.0 EU per μg of the protein as determined by the LAL method.
缓冲液	Lyophilized from sterile PBS, pH 7.4. Please contact us for any concerns or special requirements. Normally 5 % - 8 % trehalose, mannitol and 0. 01% Tween 80 are added as protectants before lyophilization. Please refer to the specific buffer information in the hard copy of CoA.
复溶方法	A hardcopy of datasheet with reconstitution instructions is sent along with the products. Please refer to it for detailed information.
存储	Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
运输方式	In general, recombinant proteins are provided as lyophilized powder which are shipped at ambient temperature.Bulk packages of recombinant proteins are provided as frozen liquid. They are shipped out with blue ice unless customers require otherwise.
研究背景	Tumor necrosis factor receptor superfamily, member 17 (TNFRSF17), also known as B cell maturation antigen (BCMA) or CD269 antigen, is a member of the TNF-receptor superfamily. This receptor is preferentially expressed in mature B lymphocytes, and may be important for B cell development and autoimmune response. This receptor has been shown to specifically bind to the tumor necrosis factor (ligand) superfamily, member 13b (TNFSF13BBAFF), and to lead to NF-kappaB and MAPK8/JNK activation. TNFRSF17/BCMA/CD269 also binds to various TRAF family members, and thus may transduce signals for cell survival and proliferation. TNFRSF17/BCMA/CD269 is a receptor for TALL-1 and BCMA activates NF-kappaB through a TRAF5-, TRAF6-, NIK-, and IKK-dependent pathway. The identification of TNFRSF17 as a NF-kappaB-activating receptor for TALL-1 suggests molecular targets for drug development against certain immunodeficient or autoimmune diseases. TNFRSF17/BCMA is a target of donor B-cell immunity in patients with myeloma who respond to DLI. Antibody responses to cell-surface BCMA may contribute directly to tumor rejection in vivo.